Skip to main content

Remote Job Finders (RJF)

Agios axes next-gen sickle cell candidate after it fails to best Novo’s asset

Agios Pharmaceuticals’ sickle cell disease candidate didn’t prove any better than Novo Nordisk’s investigational PK activator or the biopharma’s own asset that is currently under FDA review for the indication.

Novartis stays ‘geography-agnostic’ in dealmaking amid flurry of China deals

Novartis will continue to be on the lookout for bolt-on deals below $2 billion, CEO Vas Narasimhan said Tuesday on the pharma’s second quarter earnings call—though major pickups aren’t completely off the table.

Dyne gets early 2027 decision date for Duchenne therapy, analysts expect ‘smooth’ review

If approved, Dyne Therapeutics’ zeleciment rostudirsen could “capture the majority” of the exon-51 Duchenne muscular dystrophy market, given its better efficacy and dosing profile versus Sarepta Therapeutics’ exon-skipping therapy Exondys 51, the current standard of care, according to Oppenheimer.
Scroll to top